Development of a Prostate-Specific Antigen Targeted Dual Drug Conjugate for Prostate Cancer Therapy.

Area of Science:

• Oncology
• Drug Delivery
• Bioconjugation Chemistry

Background:

• Prostate cancer (PC) is a leading cause of cancer death in men, with metastatic PC lacking curative treatments.
• Current therapies for advanced PC face challenges including toxicity, cancer stem cell generation, and tumor heterogeneity.
• Targeted drug delivery strategies, like prodrugs, aim to improve efficacy and reduce systemic toxicity in advanced PC.

Purpose of the Study:

• To develop a dual drug conjugate for targeted, combination delivery of SN-38 and cabazitaxel to prostate cancer cells.
• To utilize a prostate-specific antigen (PSA) peptide recognition sequence for PC-specific drug release.
• To investigate the potential of this conjugate in treating advanced PC.

Main Methods:

• Synthesis of a dual drug conjugate linking SN-38 and cabazitaxel via a PSA-targeting peptide and click chemistry.
• In vitro evaluation of drug release triggered by exogenous PSA.
• Assessment of the conjugate's time- and concentration-dependent cytotoxicity in PC-3 and LNCaP cell lines.

Main Results:

• The synthesized dual drug conjugate successfully released cytotoxic drugs upon exposure to PSA.
• The conjugate demonstrated significant time- and concentration-dependent cytotoxicity against PC cells.
• Cytotoxicity was directly correlated with PSA expression levels in the tested cellular models.

Conclusions:

• Peptide-drug conjugates offer a promising strategy for targeted combination chemotherapy delivery in prostate cancer.
• This approach enables selective cytotoxicity towards PC cells, potentially improving treatment outcomes for advanced disease.
• The PSA-targeting dual drug conjugate warrants further investigation for its therapeutic potential in advanced prostate cancer.